Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

U Majeed, R Manochakian, Y Zhao, Y Lou - Journal of hematology & …, 2021 - Springer
Lung cancer remains the leading cause of cancer-related mortality in both men and women
in the US and worldwide. Non-small cell lung cancer is the most common variety accounting …

Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer

X Tian, T Gu, MH Lee, Z Dong - … et Biophysica Acta (BBA)-Reviews on …, 2022 - Elsevier
Lung cancer causes the highest mortality compared to other cancers in the world according
to the latest WHO reports. Non-small cell lung cancer (NSCLC) contributes about 85% of …

Clinical translation of extracellular vesicles

A Ghodasara, A Raza, J Wolfram… - Advanced …, 2023 - Wiley Online Library
Extracellular vesicles (EVs) occur in a variety of bodily fluids and have gained recent
attraction as natural materials due to their bioactive surfaces, internal cargo, and role in …

Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma

R Sun, Z Hou, Y Zhang, B Jiang - Oncology Letters, 2022 - spandidos-publications.com
According to global cancer data, lung cancer was the leading cause of cancer-related death
in 2020. With the diversification of treatment strategies, the survival outcomes of patients with …

[HTML][HTML] The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer

Z Cheng, H Cui, Y Wang, J Yang, C Lin… - Oncology …, 2024 - spandidos-publications.com
Lung cancer is currently the second most common type of cancer with the second incidence
rate and the first mortality rate worldwide. Non‑small cell lung cancer (NSCLC) accounts for …

The resistance to EGFR-TKIs in non-small cell lung cancer: from molecular mechanisms to clinical application of new therapeutic strategies

C Laface, FM Maselli, AN Santoro, ML Iaia, F Ambrogio… - Pharmaceutics, 2023 - mdpi.com
Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …

[HTML][HTML] Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States

R Roskoski Jr - Pharmacological Research, 2023 - Elsevier
Owing to genetic alterations and overexpression, the dysregulation of protein kinases plays
a significant role in the pathogenesis of many autoimmune and neoplastic disorders and …

[HTML][HTML] Resistance of lung cancer to EGFR-specific kinase inhibitors: activation of bypass pathways and endogenous mutators

I Marrocco, Y Yarden - Cancers, 2023 - mdpi.com
Simple Summary Genome-based cancer medicine is becoming the standard of care: the
patient's tumor DNA is first analyzed to identify driver mutations, and this permits later …

Design and one-pot synthesis of new substituted pyrrolo [1, 2-a] thieno [3, 2-e] pyrimidine as potential antitumor agents: in vitro and in vivo studies

IA Gorbunova, A Rogova, DR Akhmetova… - Bioorganic …, 2024 - Elsevier
A new efficient and versatile one-pot three-component synthesis of substituted pyrrolo [1, 2-
a] thieno [3, 2-e] pyrimidine derivatives has been developed. It is based on a multistep …

A review of the molecular determinants of therapeutic response in non-small cell lung cancer brain metastases

C Boldig, K Boldig, S Mokhtari, AB Etame - International Journal of …, 2024 - mdpi.com
Lung cancer is a leading cause of cancer-related morbidity and mortality worldwide.
Metastases in the brain are a common hallmark of advanced stages of the disease …